Leuven – ThromboGenics NV (Euronext Brussels: THR), biotechnology company developing novel treatments for retinal disorders, with a focus on diabetic eye disease, today announced that it will be provide business and clinical updates at a number of key investor meetings over the next few months.
- Sachs Annual Biotech in Europe Forum 2017, Basel, Switzerland – Meetings and presentation on 26 Sep 2017
- KBC Securities, Biotech & Healthcare Conference, New York, US – Meetings and presentation on 28 Sep 2017
- VFB retail investors conference, Ghent, Belgium – Meetings on 30 Sep 2017
- European Large & Midcap Event, Paris, France – Meetings on 4 Oct 2017 & 5 Oct 2017
Additional investor meetings and presentations will be announced in due time.
Earlier this week, ThromboGenics announced that it regained the full global rights to JETREA® from Alcon, a Novartis company, based on a mutual agreement that the unique characteristics of JETREA make ThromboGenics a better fit for building a sustainable long-term niche business. Under the terms of the agreement, ThromboGenics received a cash amount of €53.7 million and a forthcoming Novartis equity investment of €10 million in ThromboGenics capital.
As a result of this agreement, ThromboGenics now holds a cash position of over €120 million.
ThromboGenics has developed a world class pipeline of disease modifying drug candidates for the treatment of diabetic eye disease, particularly diabetic retinopathy (DR) and diabetic macular edma (DMA). The current drug development pipeline includes THR-409 (ocriplasmin), THR-317 (anti-PlGF), THR-149 (plasma kallikrein inhibitor), and THR-687 (integrin receptor antagonist). The company has different additional compounds and pathways in the discovery phase.